|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.44 USD | +0.46% |
|
+2.92% | +3.67% |
| 14/01 | Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating | MT |
| 13/01 | Exelixis, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 05:15 PM |
End-of-day quotes
Compared values
| Sector | Change | 5d. change | Varia. Jan 1. | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EXELIXIS, INC. | Bio Therapeutic Drugs | +0.46% | +2.92% | +3.67% | +21.92% | +91.53% | 1.22TCr |  |  | |
- Stock Market
- Equities
- EXEL Stock
- Charts Exelixis, Inc.
- Relative Strength Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition